[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07315997":3,"trial-entities:NCT07315997":103,"trial-summary:NCT07315997":108},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":20,"study_type":22,"primary_purpose":23,"phases":24,"enrollment_info":25,"interventions":28,"primary_outcomes":33,"secondary_outcomes":38,"sex":39,"minimum_age":40,"maximum_age":41,"healthy_volunteers":14,"eligibility_criteria":42,"std_ages":52,"locations":55,"central_contacts":99,"overall_officials":100,"references":101,"see_also_links":102},"NCT07315997","2024P001981","The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study","RECRUITING","2028-03-04","2025-12","2026-07-14","2024-09-04","Brigham and Women's Hospital","OTHER",false,"Individuals with rheumatoid arthritis (RA) have up to 2x the risk of having a heart attack compared to someone without RA. The goal of this study is to identify biomarkers that can help us do a better job of identifying individuals at risk before they develop symptoms of heart disease and start preventative treatment earlier.","The objective of this study is to test the utility of high sensitivity cardiac troponin (hs-cTn) and coronary artery calcium (CAC) in risk stratifying patients with rheumatoid arthritis (RA) who may benefit from lipid lowering therapy. The population of interest are individuals who would not otherwise be recommended for therapy based on general population risk calculators for heart disease risk.",[18,19],"Rheumatoid Arthritis (RA","Atherosclerotic Cardiovascular Disease (ASCVD)",[21],"CAT-RA","OBSERVATIONAL",null,[],{"count":26,"type":27},120,"ESTIMATED",[29],{"type":30,"name":31,"description":32},"DIAGNOSTIC_TEST","high sensitivity cardiac troponin","Blood measurement of high sensitivity cardiac troponin",[34],{"measure":35,"description":36,"timeFrame":37},"coronary artery calcium score","Quantified coronary artery calcium score","Cross-sectional, at baseline",[],"ALL","35 Years","79 Years",{"inclusion":43,"exclusion":47,"raw_text":51},[44,45,46],"RA diagnosed by a rheumatologist","Age 40- 79","≥1 ASCVD risk factor including prediabetes, hypertension, BMI \\>30, current or history of cigarette smoking",[48,49,50],"Patients on a statin or with a contraindication to statin, on a cholesterol absorption inhibitor, or on a PCSK9 inhibitor","Patients with diabetes mellitus","Pregnancy","Inclusion Criteria:\n\n* RA diagnosed by a rheumatologist\n* Age 40- 79\n* ≥1 ASCVD risk factor including prediabetes, hypertension, BMI \\>30, current or history of cigarette smoking\n\nExclusion Criteria:\n\n* Patients on a statin or with a contraindication to statin, on a cholesterol absorption inhibitor, or on a PCSK9 inhibitor\n* Patients with diabetes mellitus\n* Pregnancy",[53,54],"ADULT","OLDER_ADULT",[56,77,88],{"facility":57,"status":7,"city":58,"state":59,"zip":60,"country":61,"contacts":62,"geoPoint":74},"Massachusetts General Hospital: Rheumatology","Boston","Massachusetts","02114","United States",[63,68,72],{"name":64,"role":65,"phone":66,"email":67},"Sheila Arvikar, MD","CONTACT","6177267938","sarvikar@mgh.harvard.edu",{"name":69,"role":65,"phone":70,"email":71},"Abisayo Animashaun, MS","617-732-8169","aanimashaun@mgb.org",{"name":64,"role":73},"PRINCIPAL_INVESTIGATOR",{"lat":75,"lon":76},42.35843,-71.05977,{"facility":78,"status":7,"city":58,"state":59,"zip":79,"country":61,"contacts":80,"geoPoint":87},"Brigham and Womens Hospital","02115",[81,85,86],{"name":82,"role":65,"phone":83,"email":84},"Katherine P Liao, MD, MPH","617-525-8819","kliao@bwh.harvard.edu",{"name":69,"role":65,"phone":70,"email":71},{"name":82,"role":73},{"lat":75,"lon":76},{"facility":89,"status":7,"city":58,"state":59,"zip":90,"country":61,"contacts":91,"geoPoint":98},"Brigham and Women's Faulkner Hospital","02130",[92,96,97],{"name":93,"role":65,"phone":94,"email":95},"Nicole Yang, MD","6179837720","nyang2@bwh.harvard.edu",{"name":69,"role":65,"phone":70,"email":71},{"name":93,"role":73},{"lat":75,"lon":76},[],[],[],[],{"nct_id":4,"conditions":104,"biomarkers":107},[105,106],"Atherosclerosis","Rheumatoid Arthritis",[],{"nct_id":4,"found":109,"summary":110,"prompt_version":120},true,{"design":111,"status":112,"heading":113,"summary":114,"follow_up":115,"word_count":116,"commitments":117,"compensation":118,"drugs_mentioned":119},"This is an observational study, meaning participants are observed without receiving a specific treatment from the study. It plans to enroll 120 participants.","completed","The CAT-RA Study for Rheumatoid Arthritis and Heart Disease Risk","This study, called CAT-RA, is looking at how to better identify people with rheumatoid arthritis (RA) who are at higher risk for heart disease. People with RA have a greater chance of having a heart attack. Researchers are testing if measuring high sensitivity cardiac troponin (a blood test for heart damage) and coronary artery calcium (a measure of plaque in heart arteries) can help doctors find these risks earlier. This could lead to starting preventative treatments sooner. You might be able to join if you have RA, are between 35 and 79 years old, and have at least one heart disease risk factor like prediabetes or high blood pressure. The study is looking for 120 participants.","The primary endpoint, coronary artery calcium score, is measured at baseline, but no further follow-up is specified.",116,"Not specified in the trial record.","Not stated in the trial record.",[31],"v2"]